News & Media

SK life science

Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company

Here you will find the latest announcements and contact information for SK life science.

For media inquiries, please contact .

General business

Strategic alliance and partnership opportunities

Media inquiries and PR

Grant and investigator initiated proposals

Sponsorship requests

Medical information inquiries or report adverse events

SK life science at a glance

  • Headquarters location

    PARAMUS, NJ

  • R&D Begins

    1993

  • Parent Company

    SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group

  • Number of employees

    200+ EMPLOYEES

  • Disease Category Focus

    CNS

  • Pipeline

    8 compounds under clinical development

Newsroom

SK Biopharmaceuticals Initiates Clinical Development Program for Cenobamate in Asia

Full release

SK life science Expands Support for the Epilepsy Foundation to Advance Epilepsy Awareness, Research, Education and Care

Full release

Newly Published Study in Neurology Shows Cenobamate Significantly Reduced Seizure Frequency in Adults with Uncontrolled Partial-Onset (Focal) Seizures

Full release

SK life science Announces Results of Large, Open-Label Safety Study of Cenobamate Published in Epilepsia

Full release

SK life science Announces U.S. Availability of XCOPRI® (cenobamate tablets) CV for the Treatment of Partial-Onset Seizures in Adults

Full release

SK Life Science, Inc.’s Coronavirus Update

Full release

European Medicines Agency Accepts Arvelle Therapeutics’ Marketing Authorization Application for Cenobamate for the Adjunctive Treatment of Focal-Onset Seizures in Adults

Full release

SK life science Receives Schedule V Designation from DEA for XCOPRI® (cenobamate tablets)

Full release

SK life science to Present Latest Cenobamate Data at the American Epilepsy Society 2019 Annual Meeting

Full release

SK Life Science, Inc. Announces FDA Acceptance of IND Application for Anti-Epileptic Drug Candidate SKL24741

Full release